CAR T Cell Therapy Shows Promise in Acute Myeloid Leukemia

News   May 10, 2018 | Original story from Moffitt Cancer Centre

 
CAR T Cell Therapy Shows Promise in Acute Myeloid Leukemia

Relapsed AML patient treated with CYAD-01 CAR-T therapy. CD34 IHC of the core biopsy shows clusters of blasts (~7%) consistent with relapsed disease (Panel A). Prominent dysmegakaryopoiesis was also noted (Panel B). BM biopsy at day +56 following 3 infusions of CYAD-01 showed normal trilineage hematopoiesis with CD34 IHC showing no increase in blasts (Panel C). Patient also with significant improvement of hematopoiesis as transfusion independent with marked increase of hemoglobin and platelet count (Panel D). Credit: doi:10.3324/haematol.2017.186742

 
 
 

RELATED ARTICLES

$26.5M Study on Aggressive Prostate Cancer in African-American Men Begins

News

The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun.

READ MORE

Broadly Acting Antibodies Found in Blood of Ebola Survivors

News

Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.

READ MORE

New Target Protein for Colon Cancer Identified

News

Researchers at Boston University School of Medicine (BUSM) have identified a new potential target protein (c-Cbl) they believe can help further the understanding of colon cancer and ultimately survival of patients with the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy